Articles State of the Art and Science Aug 2019 Evolving Medicaid Coverage Policy and Rebates Jennifer A. Ohn, MPH and Anna Kaltenboeck, MA Ethics questions arise about the usefulness of a system that pegs Medicaid drug spending to net prices negotiated by others in the market. AMA J Ethics. 2019;21(8):E645-653. doi: 10.1001/amajethics.2019.645. Policy Forum Aug 2019 Why Are Biosimilars Not Living up to Their Promise in the US? Mike Z. Zhai, Ameet Sarpatwari, JD, PhD, and Aaron S. Kesselheim, MD, JD, MPH Overall utilization of the few biosimilars currently available to patients has been limited. AMA J Ethics. 2019;21(8):E668-678. doi: 10.1001/amajethics.2019.668. Policy Forum Aug 2019 Should a Law Governing the Pharmaceutical Market Be Ethically Examined Based on Its Intent or Its Practical Applications? Jordan M. Warchol, MD, MPH In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013. AMA J Ethics. 2019;21(8):E661-667. doi: 10.1001/amajethics.2019.661. Art of Medicine Aug 2019 Normal Saline Hannah Rebeccah Abrams This graphic narrative considers the shortage of normal saline in US health care organizations after Hurricane Maria devastated Puerto Rico in 2017. AMA J Ethics. 2019;21(8):E699-700. doi: 10.1001/amajethics.2019.699. State of the Art and Science Aug 2019 Are Medicaid Closed Formularies Unethical? Leah Rand, DPhil and Govind Persad, JD, PhD Closed formularies can be justified when they enable spending on other socially valuable aims, but they can single out poor patients. AMA J Ethics. 2019;21(8):E654-660. doi: 10.1001/amajethics.2019.654. Medical Education Aug 2019 How Should Medical Education Better Prepare Physicians for Opioid Prescribing? Rohanit Singh and Gary W. Pushkin, MD Case-based teaching, longitudinal application, and training in ethical deliberation can better prepare physicians to responsibly prescribe and manage opioids. AMA J Ethics. 2019;21(8):E636-641. doi: 10.1001/amajethics.2019.636. AMA Code Says Aug 2019 AMA Code of Medical Ethics’ Opinions Related to Prescription Drugs Rachel F. Harbut and Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics offers guidance on stewardship and professionalism. AMA J Ethics. 2019;21(8):E642-644. doi: 10.1001/amajethics.2019.642. Case and Commentary Jul 2019 Should Aggregate Patient Preference Data Be Used to Make Decisions on Behalf of Unrepresented Patients? Nathaniel Sharadin, PhD, MA Ethical and practical problems with preference modeling can undermine how reliably predictors can be used in high-stakes decisions. AMA J Ethics. 2019;21(7):E566-574. doi: 10.1001/amajethics.2019.566. Health Law Jul 2019 Regional Unrepresented Patient Advocacy Committee as an Alternative for Decision Making Lisa K. Anderson-Shaw, DrPH, MA, MSN, ANP-BC A UPAC is an alternative to engaging a guardianship court appointment process or to using physicians or ethics committees as decision makers. AMA J Ethics. 2019;21(7):E594-599. doi: 10.1001/amajethics.2019.594. Case and Commentary Jul 2019 When There’s No One to Whom an Error Can Be Disclosed, How Should an Error Be Handled? Ryan G. Chiu When a patient is incompetent and unrepresented, alternative strategies must be implemented to document and try to rectify an error. AMA J Ethics. 2019;21(7):E553-558. doi: 10.1001/amajethics.2019.553. Pagination First page « First Previous page ‹ Prev … Page 94 Page 95 Page 96 Page 97 Current page 98 Page 99 Page 100 Page 101 Page 102 … Next page Next › Last page Last »
State of the Art and Science Aug 2019 Evolving Medicaid Coverage Policy and Rebates Jennifer A. Ohn, MPH and Anna Kaltenboeck, MA Ethics questions arise about the usefulness of a system that pegs Medicaid drug spending to net prices negotiated by others in the market. AMA J Ethics. 2019;21(8):E645-653. doi: 10.1001/amajethics.2019.645.
Policy Forum Aug 2019 Why Are Biosimilars Not Living up to Their Promise in the US? Mike Z. Zhai, Ameet Sarpatwari, JD, PhD, and Aaron S. Kesselheim, MD, JD, MPH Overall utilization of the few biosimilars currently available to patients has been limited. AMA J Ethics. 2019;21(8):E668-678. doi: 10.1001/amajethics.2019.668.
Policy Forum Aug 2019 Should a Law Governing the Pharmaceutical Market Be Ethically Examined Based on Its Intent or Its Practical Applications? Jordan M. Warchol, MD, MPH In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013. AMA J Ethics. 2019;21(8):E661-667. doi: 10.1001/amajethics.2019.661.
Art of Medicine Aug 2019 Normal Saline Hannah Rebeccah Abrams This graphic narrative considers the shortage of normal saline in US health care organizations after Hurricane Maria devastated Puerto Rico in 2017. AMA J Ethics. 2019;21(8):E699-700. doi: 10.1001/amajethics.2019.699.
State of the Art and Science Aug 2019 Are Medicaid Closed Formularies Unethical? Leah Rand, DPhil and Govind Persad, JD, PhD Closed formularies can be justified when they enable spending on other socially valuable aims, but they can single out poor patients. AMA J Ethics. 2019;21(8):E654-660. doi: 10.1001/amajethics.2019.654.
Medical Education Aug 2019 How Should Medical Education Better Prepare Physicians for Opioid Prescribing? Rohanit Singh and Gary W. Pushkin, MD Case-based teaching, longitudinal application, and training in ethical deliberation can better prepare physicians to responsibly prescribe and manage opioids. AMA J Ethics. 2019;21(8):E636-641. doi: 10.1001/amajethics.2019.636.
AMA Code Says Aug 2019 AMA Code of Medical Ethics’ Opinions Related to Prescription Drugs Rachel F. Harbut and Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics offers guidance on stewardship and professionalism. AMA J Ethics. 2019;21(8):E642-644. doi: 10.1001/amajethics.2019.642.
Case and Commentary Jul 2019 Should Aggregate Patient Preference Data Be Used to Make Decisions on Behalf of Unrepresented Patients? Nathaniel Sharadin, PhD, MA Ethical and practical problems with preference modeling can undermine how reliably predictors can be used in high-stakes decisions. AMA J Ethics. 2019;21(7):E566-574. doi: 10.1001/amajethics.2019.566.
Health Law Jul 2019 Regional Unrepresented Patient Advocacy Committee as an Alternative for Decision Making Lisa K. Anderson-Shaw, DrPH, MA, MSN, ANP-BC A UPAC is an alternative to engaging a guardianship court appointment process or to using physicians or ethics committees as decision makers. AMA J Ethics. 2019;21(7):E594-599. doi: 10.1001/amajethics.2019.594.
Case and Commentary Jul 2019 When There’s No One to Whom an Error Can Be Disclosed, How Should an Error Be Handled? Ryan G. Chiu When a patient is incompetent and unrepresented, alternative strategies must be implemented to document and try to rectify an error. AMA J Ethics. 2019;21(7):E553-558. doi: 10.1001/amajethics.2019.553.
